The p53abn-RED trial: Institute Gustave Roussy
Welcome,         Profile    Billing    Logout  
 1 Trial 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LEARY, Alexandra
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
RAINBO-RED, NCT06712472: Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer

Recruiting
3
554
Europe
Olaparib (300 mg BID)
Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca
Endometrial Cancer, P53abn
06/30
12/31
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
06/28
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
ROCSAN, NCT03651206: Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Hourglass Jan 2019 - Jan 2019 : Initiation of P2/3 ROCSAN trial for recurrent ovarian carcinosarcoma
Active, not recruiting
2/3
196
Europe
Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
ARCAGY/ GINECO GROUP, Tesaro, Inc.
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
12/24
06/25
RAINBO, NCT05255653: Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Recruiting
2/3
1615
Europe, Canada
Olaparib, Lynparza, Pelvic external beam radiotherapy, EBRT, Chemotherapy, Cisplatin, Carboplatin, Paclitaxel, Durvalumab, Imfinzi, Medroxyprogesterone Acetate, Progestogen, Megestrol Acetate, Vaginal brachytherapy, Observation
Leiden University Medical Center, Institute Gustave Roussy (sponsor p53abn-RED trial), Leiden University Medical center (sponsor MMRd-GREEN trial), University College London (sponsor NSMP-ORANGE trial), Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial), Dutch Gynaecological Oncology Group, Comprehensive Cancer Centre The Netherlands, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR)
Endometrial Cancer
01/30
01/31
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Recruiting
2
77
Europe
combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone
ARCAGY/ GINECO GROUP
LOCALLY ADVANCED CERVICAL CANCERS
12/30
12/30
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
GYNET, NCT04652076 / 2020-000172-38: GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting
1/2
240
Europe
NP137, Pembrolizumab, KEYTRUDA, Paclitaxel, Carboplatin
NETRIS Pharma, Merck Sharp & Dohme LLC, Centre Leon Berard
Endometrial Carcinoma, Cervix Carcinoma
10/25
07/26
INeOV, NCT03249142: Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

Active, not recruiting
1/2
69
Europe
ARM A Durvalumab/chemotherapy association, ARM B Durvalumab/Tremelimumab/chemotherapy association
ARCAGY/ GINECO GROUP, AstraZeneca
Ovarian Cancer
12/24
12/24
OvBIOMark, NCT03010124: Prognostic and Predictive Biomarkers in Ovarian Cancers

Recruiting
N/A
350
Europe
Blood sample
Gustave Roussy, Cancer Campus, Grand Paris
Ovarian Cancer
09/30
09/32
MOSAIC, NCT06625203: A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

Recruiting
N/A
7000
Europe, US
OWKIN
Diffuse Large B Cell Lymphoma, Solid Tumor Cancer
12/28
12/28

Download Options